Robert Cavorsi - Apr 19, 2024 Form 3 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
Vice President, Strategy
Signature
/s/ William R. Kolb, Attorney-in-Fact
Stock symbol
ORGO
Transactions as of
Apr 19, 2024
Transactions value $
$0
Form type
3
Date filed
4/29/2024, 04:22 PM
Next filing
Jul 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ORGO Class A Common Stock 23.6K Apr 19, 2024 Direct F2
holding ORGO Class A Common Stock 739 Apr 19, 2024 Direct F1, F3
holding ORGO Class A Common Stock 215 Apr 19, 2024 Direct F1, F3
holding ORGO Class A Common Stock 2.16K Apr 19, 2024 Direct F1, F4
holding ORGO Class A Common Stock 4.2K Apr 19, 2024 Direct F1, F5
holding ORGO Class A Common Stock 51.8K Apr 19, 2024 Direct F1, F6
holding ORGO Class A Common Stock 57.4K Apr 19, 2024 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ORGO Stock Option (Right to Buy) Apr 19, 2024 Class A Common Stock 6.52K $15.63 Direct F8
holding ORGO Stock Option (Right to Buy) Apr 19, 2024 Class A Common Stock 32.6K $14.45 Direct F9
holding ORGO Stock Option (Right to Buy) Apr 19, 2024 Class A Common Stock 19.9K $8.03 Direct F10
holding ORGO Stock Option (Right to Buy) Apr 19, 2024 Class A Common Stock 81K $2.51 Direct F11
holding ORGO Stock Option (Right to Buy) Apr 19, 2024 Class A Common Stock 104K $3.43 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.
F2 Represents shares of Class A Common Stock of Organogenesis pursuant to vested RSUs under the 2018 Equity Incentive Plan.
F3 The RSUs vest in equal annual installments over four years beginning March 9, 2021, and shall become fully vested on March 9, 2025.
F4 The RSUs vest in equal annual installments over four years beginning July 16, 2021, and shall become fully vested on July 16, 2025.
F5 The RSUs vest in equal annual installments over four years beginning March 1, 2022, and shall become fully vested on March 1, 2026.
F6 The RSUs vest in equal annual installments over four years beginning February 15, 2023, and shall become fully vested on February 15, 2027.
F7 The RSUs vest in equal annual installments over four years beginning February 15, 2024, and shall become fully vested on February 15, 2028.
F8 The option becomes exercisable in equal annual installments over four years beginning March 9, 2021, and shall become fully vested and exercisable on March 9, 2025.
F9 The option becomes exercisable in equal annual installments over four years beginning July 16, 2021, and shall become fully vested and exercisable on July 16, 2025.
F10 The option becomes exercisable in equal annual installments over four years beginning March 1, 2022, and shall become fully vested and exercisable on March 1, 2026.
F11 The option becomes exercisable in equal annual installments over four years beginning February 15, 2023, and shall become fully vested and exercisable on February 15, 2027.
F12 The option becomes exercisable in equal annual installments over four years beginning February 15, 2024, and shall become fully vested and exercisable on February 15, 2028.

Remarks:

Exhibit 24 Power of Attorney filed herewith.